

**Safety and Tolerability of Cariprazine in Patients with Schizophrenia: A Pooled Analysis of Eight Phase II/III Studies [Corrigendum]**

Barabássy Á, Sebe B, Acsai K, et al. *Neuropsychiatr Dis Treat.* 2021;17:957–970.

read “2 (0.3)”. Total 1.5-6 mg/d column, “0” should read “3 (0.1)”.

The authors have advised that there are errors in the first row of Table 5 on page 963.

The authors apologize for these errors.

Cariprazine 4.5 mg column, the value “1 (0.0)” should read “1 (0.2)”. Cariprazine 6 mg column, “2 (0.0)” should

**Publish your work in this journal**

Neuropsychiatric Disease and Treatment is an international, peer-reviewed journal of clinical therapeutics and pharmacology focusing on concise rapid reporting of clinical or pre-clinical studies on a range of neuropsychiatric and neurological disorders. This journal is indexed on PubMed Central, the ‘PsycINFO’ database and CAS, and

is the official journal of The International Neuropsychiatric Association (INA). The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.

Submit your manuscript here: <https://www.dovepress.com/neuropsychiatric-disease-and-treatment-journal>

